Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534583 | 0.85 | HDAC1 (1.00) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL4541855 | 0.81 | HDAC1 (1.00) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL5225255 | 0.80 | KCNH2 (0.76) | HDAC1HDAC3HDAC2KCNH2 | |
| SCHEMBL5224592 | 0.78 | HDAC1 (0.72) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL8161162 | 0.77 | HDAC1 (0.70) | HDAC1HDAC3HDAC2KCNH2 | |
| SCHEMBL4541772 | 0.76 | HDAC1 (1.00) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL2410399 | 0.76 | HDAC1 (0.65) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL5038130 | 0.76 | HDAC1 (0.73) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL4541782 | 0.76 | HDAC1 (1.00) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL4541780 | 0.76 | HDAC1 (1.00) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105264-A1 | Substituted Nicotinamide Compounds | MERCK SHARP & DOHME CORP. | 2009-04-23 | — | — | US | claimed |
| EP-1945028-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | Merck & Co., Inc. (US) | 2008-07-23 | — | — | EP | claimed |
| WO-2007055942-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | claimed |
| US-20090105264-A1 | Substituted Nicotinamide Compounds | MERCK SHARP & DOHME CORP. | 2009-04-23 | — | — | US | disclosed |
| EP-1945028-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | Merck & Co., Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007055942-A2 | SUBSTITUTED NICOTINAMIDE COMPOUNDS | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105264-A1 | Substituted Nicotinamide Compounds | SIRT1, NQO1, TXNRD2 | HDAC1 15/4885HDAC3 16/4885CYP2C9 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.